Group One Trading
CLSD

Group One Trading’s Clearside Biomedical CLSD Stock Holding History

Group One Trading’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,593
Closed -$35.7K – 8004
2025
Q1 		$35.7K Sell
2,593
-6,774
-72% -$97.3K ﹤0.01% 5417
2024
Q4 		$133K Buy
9,367
+3,800
+68% +$62.5K ﹤0.01% 4273
2024
Q3 		$106K Buy
5,567
+2,647
+91% +$45.2K ﹤0.01% 4129
2024
Q2 		$56.9K Sell
2,920
-80
-3% -$1.55K ﹤0.01% 4425
2024
Q1 		$68.8K Buy
3,000
+1,200
+67% +$25.9K ﹤0.01% 4442
2023
Q4 		$31.6K Sell
1,800
-7
-0.4% -$100 ﹤0.01% 5405
2023
Q3 		$23.6K Hold
1,807
– – ﹤0.01% 5761
2023
Q2 		$30.4K Sell
1,807
-213
-11% -$3.67K ﹤0.01% 5672
2023
Q1 		$31.5K Sell
2,020
-4,100
-67% -$79.6K ﹤0.01% 5200
2022
Q4 		$103K Buy
6,120
+107
+2% +$1.93K ﹤0.01% 4418
2022
Q3 		$102K Sell
6,013
-1,200
-17% -$26.3K ﹤0.01% 4755
2022
Q2 		$159K Buy
7,213
+220
+3% +$5.34K ﹤0.01% 4516
2022
Q1 		$240K Buy
6,993
+4,046
+137% +$121K ﹤0.01% 4607
2021
Q4 		$122K Sell
2,947
-3,093
-51% -$200K ﹤0.01% 5549
2021
Q3 		$544K Sell
6,040
-6,620
-52% -$584K ﹤0.01% 4100
2021
Q2 		$925K Buy
12,660
+8,133
+180% +$378K ﹤0.01% 3507
2021
Q1 		$168K Buy
4,527
+4,420
+4,131% +$222K ﹤0.01% 5199
2020
Q4 		$4K Sell
107
-1,606
-94% -$41.7K ﹤0.01% 6083
2020
Q3 		$40K Buy
1,713
+1,313
+328% +$33.9K ﹤0.01% 4778
2020
Q2 		$11K Sell
400
-3,387
-89% -$99.7K ﹤0.01% 5072
2020
Q1 		$97K Sell
3,787
-873
-19% -$32.3K ﹤0.01% 3320
2019
Q4 		$203K Buy
+4,660
New +$97.9K ﹤0.01% 3159
2019
Q3 		– Sell
-2,673
Closed -$39K – 5182
2019
Q2 		$39K Sell
2,673
-1,300
-33% -$23.2K ﹤0.01% 3898
2019
Q1 		$82K Buy
3,973
+3,420
+618% +$67.9K ﹤0.01% 3301
2018
Q4 		$9K Buy
553
+426
+335% +$20K ﹤0.01% 4299
2018
Q3 		$12K Sell
127
-666
-84% -$79.2K ﹤0.01% 4590
2018
Q2 		$127K Sell
793
-1,360
-63% -$229K ﹤0.01% 3397
2018
Q1 		$347K Buy
+2,153
New +$262K ﹤0.01% 2342

Other funds holding CLSD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Group One Trading's CLSD Position: Q4 2024 in Review

Group One Trading sold out of Clearside Biomedical (CLSD) in Q4 2024, closing a stake of 908 shares — an estimated $14.9K sold.

Group One Trading first reported a position in CLSD in Q1 2018 and held it in 19 quarters. The position peaked at $1.07M in Q2 2020. 43 funds tracked by Wall St. Rank hold CLSD as of Q4 2024.

  • Group One Trading reported no remaining Clearside Biomedical position as of Q4 2024 after selling out during the quarter.
  • Group One Trading sold 908 Clearside Biomedical shares in Q4 2024, an estimated $14.9K.
  • Group One Trading first reported a position in Clearside Biomedical in Q1 2018 and held it in 19 quarters.
  • Group One Trading's Clearside Biomedical position peaked at $1.07M in Q2 2020.
  • 43 funds tracked by Wall St. Rank held Clearside Biomedical as of Q4 2024.

Based on Group One Trading's 13F filing for Q4 2024, filed 14 Feb 2025.